Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,changeToNetincome,capitalExpenditures,depreciation,changeToInventory,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,EVT.DE,443312000.0,164560992,18460000,,54440000,,52702000,21194000,30679000,6778000,6778000,-15753000,-2314000,,,,1738000,133085000,126307000,102406000,47662000,,52702000,52702000,95693000.0,1032129000.0,787661000.0,793046000.0,154581000.0,1580707000.0,164561000.0,-381249000.0,61122000.0,254041000.0,-22395000.0,67368000.0,401597000.0,239606000.0,25673000.0,15264000.0,-22395000.0,374930000.0,680401000.0,108274000.0,68979000.0,154670000.0,353201000.0,15237000.0,54880000.0,,-7656000.0,0.0,-46504000.0,17285000.0,17931000.0,-21968000.0,646000.0,-20983000.0,5131000.0,2459000.0,-28275000.0,-36297000.0,,,,440795000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,0.4275542,41.59 - 42.81,42.1,42.33,42.37,1053,1693,finmb_531375,XETRA,EUR,333663,271950,20.919998,0.97940063,21.36 - 44.05,-1.7700005,-0.040181622,21.36,44.05,1636615800,1636615800,1636615800,158.94736,0.266,0.35,7200000,4.833,38.29639,3.9836082,0.10402046,34.995,7.285,2,EVOTEC SE,Evotec SE,42.28,1630510191,0.1800003,42.2,42.81,41.59,315543,POST,GER,de_market,0.2081726,6957638656,120.799995,8.748189,15,Europe/Berlin,CEST,False,False,0,0.87,,,44.05,21.36,38.3,34.99,333.66k,271.95k,164.56M,,125.38M,15.76%,64.20%,,,,,,,,,,,0.00%,,,2:1,"Aug 18, 2000","Dec 31, 2020","Mar 31, 2021",8.14%,8.10%,1.89%,6.53%,514.61M,3.28,11.50%,125.74M,80.22M,41.88M,0.27,208.60%,470.58M,2.87,517.08M,65.20,2.84,4.83,20.05M,-57.12M,Value,22419,Healthcare,3735,7,5,"Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.",Hamburg,49 40 5 60 81 0,1,1609372800,1622505600,7,Germany,http://www.evotec.com,86400,6,Manfred Eigen Campus,49 40 5 60 81 222,Drug Manufacturers—Specialty & Generic,Essener Bogen 7
t-1,EVT.DE,375866000.0,164560992,17868000,,6461000,,403000,18706000,36554000,15725000,15725000,-15745000,-3737000,,,,6058000,140510000,124785000,103956000,-9264000,,403000,403000,99610000.0,1030702000.0,740049000.0,722846000.0,99899000.0,1462895000.0,163915000.0,-434249000.0,69633000.0,247370000.0,-37522000.0,62327000.0,422580000.0,208459000.0,24950000.0,15180000.0,-37522000.0,335723000.0,658844000.0,59021000.0,70054000.0,122221000.0,331019000.0,13585000.0,42549000.0,21146000.0,-11339000.0,-12453000.0,-72234000.0,-9422000.0,241147000.0,10661000.0,250569000.0,206680000.0,13830000.0,23937000.0,-38409000.0,-43724000.0,53331000.0,-3631000.0,-4178000.0,450385000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,0.4275542,41.59 - 42.81,42.1,42.33,42.37,1053,1693,finmb_531375,XETRA,EUR,333663,271950,20.919998,0.97940063,21.36 - 44.05,-1.7700005,-0.040181622,21.36,44.05,1636615800,1636615800,1636615800,158.94736,0.266,0.35,7200000,4.833,38.29639,3.9836082,0.10402046,34.995,7.285,2,EVOTEC SE,Evotec SE,42.28,1630510191,0.1800003,42.2,42.81,41.59,315543,POST,GER,de_market,0.2081726,6957638656,120.799995,8.748189,15,Europe/Berlin,CEST,False,False,0,0.87,,,44.05,21.36,38.3,34.99,333.66k,271.95k,164.56M,,125.38M,15.76%,64.20%,,,,,,,,,,,0.00%,,,2:1,"Aug 18, 2000","Dec 31, 2020","Mar 31, 2021",8.14%,8.10%,1.89%,6.53%,514.61M,3.28,11.50%,125.74M,80.22M,41.88M,0.27,208.60%,470.58M,2.87,517.08M,65.20,2.84,4.83,20.05M,-57.12M,Value,22419,Healthcare,3735,7,5,"Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.",Hamburg,49 40 5 60 81 0,1,1609372800,1622505600,7,Germany,http://www.evotec.com,86400,6,Manfred Eigen Campus,49 40 5 60 81 222,Drug Manufacturers—Specialty & Generic,Essener Bogen 7
t-2,EVT.DE,119497000.0,164560992,16281000,,7522000,,-1410000,21600000,36124000,16369000,16369000,-18126000,-1352000,,,,8932000,129425000,113056000,93301000,-8847000,,-1410000,-1410000,105800000.0,790703000.0,696899000.0,472772000.0,121807000.0,1169671000.0,151897000.0,-435395000.0,76290000.0,247475000.0,-34433000.0,66462000.0,215900000.0,194875000.0,25040000.0,15696000.0,-34433000.0,270291000.0,427185000.0,52458000.0,42059000.0,129137000.0,330979000.0,11689000.0,44142000.0,,-3069000.0,0.0,-29703000.0,-3107000.0,-2659000.0,6615000.0,448000.0,-8536000.0,-3929000.0,27755000.0,50901000.0,-26634000.0,-28351000.0,-3631000.0,-4178000.0,232310000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,0.4275542,41.59 - 42.81,42.1,42.33,42.37,1053,1693,finmb_531375,XETRA,EUR,333663,271950,20.919998,0.97940063,21.36 - 44.05,-1.7700005,-0.040181622,21.36,44.05,1636615800,1636615800,1636615800,158.94736,0.266,0.35,7200000,4.833,38.29639,3.9836082,0.10402046,34.995,7.285,2,EVOTEC SE,Evotec SE,42.28,1630510191,0.1800003,42.2,42.81,41.59,315543,POST,GER,de_market,0.2081726,6957638656,120.799995,8.748189,15,Europe/Berlin,CEST,False,False,0,0.87,,,44.05,21.36,38.3,34.99,333.66k,271.95k,164.56M,,125.38M,15.76%,64.20%,,,,,,,,,,,0.00%,,,2:1,"Aug 18, 2000","Dec 31, 2020","Mar 31, 2021",8.14%,8.10%,1.89%,6.53%,514.61M,3.28,11.50%,125.74M,80.22M,41.88M,0.27,208.60%,470.58M,2.87,517.08M,65.20,2.84,4.83,20.05M,-57.12M,Value,22419,Healthcare,3735,7,5,"Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.",Hamburg,49 40 5 60 81 0,1,1609372800,1622505600,7,Germany,http://www.evotec.com,86400,6,Manfred Eigen Campus,49 40 5 60 81 222,Drug Manufacturers—Specialty & Generic,Essener Bogen 7
t-3,EVT.DE,117759000.0,164560992,14740000,,-7046000,,-9817000,19278000,19793000,2822000,2822000,-17047000,-2639000,,,,2771000,111587000,108765000,91794000,-9868000,,-9817000,-9817000,109132000.0,789424000.0,714599000.0,476079000.0,120360000.0,1190678000.0,151450000.0,-433883000.0,66894000.0,249188000.0,-30912000.0,68763000.0,224436000.0,181487000.0,31864000.0,6101000.0,-30912000.0,264256000.0,445584000.0,53755000.0,51986000.0,128007000.0,340923000.0,10597000.0,37473000.0,,-27271000.0,0.0,-39644000.0,11302000.0,11523000.0,-44389000.0,221000.0,-60974000.0,1250000.0,-34103000.0,-8248000.0,-12373000.0,28351000.0,-3631000.0,-4178000.0,264097000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,0.4275542,41.59 - 42.81,42.1,42.33,42.37,1053,1693,finmb_531375,XETRA,EUR,333663,271950,20.919998,0.97940063,21.36 - 44.05,-1.7700005,-0.040181622,21.36,44.05,1636615800,1636615800,1636615800,158.94736,0.266,0.35,7200000,4.833,38.29639,3.9836082,0.10402046,34.995,7.285,2,EVOTEC SE,Evotec SE,42.28,1630510191,0.1800003,42.2,42.81,41.59,315543,POST,GER,de_market,0.2081726,6957638656,120.799995,8.748189,15,Europe/Berlin,CEST,False,False,0,0.87,,,44.05,21.36,38.3,34.99,333.66k,271.95k,164.56M,,125.38M,15.76%,64.20%,,,,,,,,,,,0.00%,,,2:1,"Aug 18, 2000","Dec 31, 2020","Mar 31, 2021",8.14%,8.10%,1.89%,6.53%,514.61M,3.28,11.50%,125.74M,80.22M,41.88M,0.27,208.60%,470.58M,2.87,517.08M,65.20,2.84,4.83,20.05M,-57.12M,Value,22419,Healthcare,3735,7,5,"Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.",Hamburg,49 40 5 60 81 0,1,1609372800,1622505600,7,Germany,http://www.evotec.com,86400,6,Manfred Eigen Campus,49 40 5 60 81 222,Drug Manufacturers—Specialty & Generic,Essener Bogen 7
